Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma.

Morimoto Y, Nouso K, Wada N, Takeuchi Y, Kinugasa H, Miyahara K, Yasunaka T, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K.

Hepatol Res. 2014 Dec;44(14):E353-9. doi: 10.1111/hepr.12315. Epub 2014 Mar 25.

PMID:
24552350
2.

Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy.

Jun L, Zhenlin Y, Renyan G, Yizhou W, Xuying W, Feng X, Yong X, Kui W, Jian L, Dong W, Hongyang W, Lehua S, Mengchao W, Feng S.

Oncologist. 2012;17(7):963-9. doi: 10.1634/theoncologist.2011-0447. Epub 2012 May 31.

3.

High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization.

Xue TC, Ge NL, Xu X, Le F, Zhang BH, Wang YH.

Hepatol Res. 2016 Sep;46(10):1028-36. doi: 10.1111/hepr.12651. Epub 2016 Mar 10.

PMID:
26776560
4.

Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors.

Kanda M, Tateishi R, Yoshida H, Sato T, Masuzaki R, Ohki T, Imamura J, Goto T, Yoshida H, Hamamura K, Obi S, Kanai F, Shiina S, Omata M.

Liver Int. 2008 Nov;28(9):1256-63. doi: 10.1111/j.1478-3231.2008.01864.x. Epub 2008 Jul 15.

PMID:
18710423
5.

Management of patients with hepatocellular carcinoma and extrahepatic metastasis.

Lee HS.

Dig Dis. 2011;29(3):333-8. doi: 10.1159/000327572. Epub 2011 Aug 9. Review.

PMID:
21829026
6.

Screening for extrahepatic metastases by additional staging modalities is required for hepatocellular carcinoma patients beyond modified UICC stage T1.

Yi J, Gwak GY, Sinn DH, Kim YJ, Kim HN, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Hepatogastroenterology. 2013 Mar-Apr;60(122):328-32.

PMID:
23241421
7.

Segregation of signaling proteins as prognostic predictors for local recurrence and distant metastasis in hepatocellular carcinoma.

Yeh CT, Huang YH, Liang KH, Chang ML, Hsu CW, Chen YC, Chen TC, Yeh TS, Lee WC.

Int J Oncol. 2014 Feb;44(2):491-504. doi: 10.3892/ijo.2013.2198. Epub 2013 Nov 29.

PMID:
24297625
8.

Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.

Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K.

Cancer. 2011 Oct 1;117(19):4475-83. doi: 10.1002/cncr.25960. Epub 2011 Mar 22.

9.

Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases.

Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, Choi JY, Yoon SK, Chung KW, Kay CS, Jung HS.

J Gastroenterol Hepatol. 2012 Apr;27(4):684-9. doi: 10.1111/j.1440-1746.2011.06917.x.

PMID:
21916984
10.

Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma.

Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, Makuuchi M, Kawasaki S.

Br J Surg. 1999 Aug;86(8):1032-8.

PMID:
10460639
11.

Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.

Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY.

J Vasc Interv Radiol. 2011 Jul;22(7):917-23. doi: 10.1016/j.jvir.2011.03.005. Epub 2011 May 14.

PMID:
21571545
12.

The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.

Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M, Yano M.

Cancer. 2003 Dec 15;98(12):2671-7.

13.

Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma.

Tang W, Kokudo N, Sugawara Y, Guo Q, Imamura H, Sano K, Karako H, Qu X, Nakata M, Makuuchi M.

Oncol Rep. 2005 Jan;13(1):25-30.

PMID:
15583797
14.

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V.

World J Hepatol. 2012 Sep 27;4(9):256-61. doi: 10.4254/wjh.v4.i9.256.

15.

High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.

Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H.

Cancer. 2009 Feb 1;115(3):571-80. doi: 10.1002/cncr.24031.

16.

Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.

Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M.

Int J Oncol. 2003 May;22(5):969-75.

PMID:
12684661
17.
18.

Clinical features of hepatocellular carcinoma with extrahepatic metastases.

Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M.

J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7.

PMID:
16246200
19.
20.

Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.

Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N.

Liver Int. 2011 Jan;31(1):22-35. doi: 10.1111/j.1478-3231.2010.02348.x. Epub 2010 Sep 27. Review.

PMID:
20874725

Supplemental Content

Support Center